Provided by Tiger Trade Technology Pte. Ltd.

TG Therapeutics

53.96
-1.4350-2.59%
Volume:1.03M
Turnover:55.95M
Market Cap:8.26B
PE:19.49
High:56.26
Open:55.71
Low:53.47
Close:55.39
52wk High:59.30
52wk Low:26.76
Shares:153.09M
Float Shares:141.54M
Volume Ratio:0.81
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.77
EPS(LYR):2.77
ROE:100.28%
ROA:7.28%
PB:13.67
PE(LYR):19.48

Loading ...

TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewswire
·
Sep 10

TG Therapeutics CEO Michael Weiss to Join Cantor Global Healthcare Conference Fireside Chat

Reuters
·
Sep 03

B. Riley Securities Remains a Buy on TG Therapeutics (TGTX)

TIPRANKS
·
Sep 02

TG Therapeutics Price Target Maintained with a $78.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 02

Analysts Offer Insights on Healthcare Companies: Adicet Bio (ACET) and TG Therapeutics (TGTX)

TIPRANKS
·
Sep 02

TG Therapeutics (TGTX) Tests A Key Moving Average, Is The Stock Fully Priced?

Simply Wall St.
·
Aug 25

TG Therapeutics Advances Injectable MS Therapy With New Phase 2 Device Study

TIPRANKS
·
Aug 22

Movement Alert|TG Therapeutics Rises 9.39% in Regular Trading, Trading at $55.29

Market Focus
·
Aug 22

TG Therapeutics rumor highlighted in Betaville blog

TIPRANKS
·
Aug 21

TG Therapeutics jumps 4% to $52.82 after Betaville mention

TIPRANKS
·
Aug 21

How TG Therapeutics’ Q2 2026 Revenue Surge And Higher Guidance At TG Therapeutics (TGTX) Has Changed Its Investment Story

Simply Wall St.
·
Aug 16

TG Therapeutics (TGTX) Raised Revenue Guidance After Q2, Is It Still Below Fair Value?

Simply Wall St.
·
Aug 14

TG Therapeutics price target raised to $21 from $20 at BofA

TIPRANKS
·
Aug 06

TG Therapeutics (TGTX) Looks Fairly Valued After Raised 2026 Guidance And Mixed Q2 Earnings

Simply Wall St.
·
Aug 06

Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX), Syndax Pharmaceuticals (SNDX) and DaVita (DVA)

TIPRANKS
·
Aug 05

TG Therapeutics Earnings Call Signals BRIUMVI Surge

TIPRANKS
·
Aug 05

Movement Alert|TG Therapeutics Rises 5.01% in Regular Trading, Rebounding as Market Re-Prices Q2 Revenue Beat and Raised Full-Year Guidance

Market Focus
·
Aug 05

Palvella Therapeutics Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 04

Switzerland's Crispr Therapeutics Q2 Casgevy Revenue Jumps 151%, Net Loss Narrows on FDA Approval for Expansion

Reuters
·
Aug 04

Stoke Therapeutics Q2 Revenue Falls 33% on Lower Collaboration, Licensing Income

Reuters
·
Aug 04